Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Laudon

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Naunyn-Schmiedeberg'S Archives of Pharmacology|February 23, 2016
Melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, attenuates TNBS-induced colitis in miceMarta Zielińska, Agata Jarmuż, Maciej Sałaga, et al.
Neuro Endocrinology Letters|August 27, 2002
Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid systemPaolo Lissoni, Fabio Malugani, Ola Malysheva, et al.
Hormones and Behavior|May 9, 2013
A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' diseasePingping He, Xinping Ouyang, Shouhong Zhou, et al.
Journal of Alzheimer'S Disease : JAD|May 28, 2017
CD44 Splice Variants as Potential Players in Alzheimer's Disease PathologyElhanan Pinner, Yaron Gruper, Micha Ben Zimra, et al.
BMC Medicine|August 18, 2010
Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safetyAlan G Wade, Ian Ford, Gordon Crawford, et al.
Current Medical Research and Opinion|November 25, 2010
Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term responseAlan G Wade, Gordon Crawford, Ian Ford, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 14, 2017
Melatonin Receptor Agonist Piromelatine Ameliorates Impaired Glucose Metabolism in Chronically Stressed Rats Fed a High-Fat DietJun Zhou, Deng Wang, XiaoHong Luo, et al.
European Journal of Pharmacology|February 4, 2014
Piromelatine, a novel melatonin receptor agonist, stabilizes metabolic profiles and ameliorates insulin resistance in chronic sleep restricted ratsMeihua She, Xiaobo Hu, Zehong Su, et al.
European Journal of Pharmacology|July 9, 2017
Neu-P11, a novel MT1/MT2 agonist, reverses diabetes by suppressing the hypothalamic-pituitary-adrenal axis in ratsJun Zhou, Jin Zhang, XiaoHong Luo, et al.
Acta Biochimica Et Biophysica Sinica|March 31, 2016
Role of Neu-p11/luzindole in the regulation of insulin signaling pathways and insulin resistanceXiuping Li, Shichang Cai, Weidong Yin, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Naunyn-Schmiedeberg'S Archives of Pharmacology|February 23, 2016
Melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, attenuates TNBS-induced colitis in miceMarta Zielińska, Agata Jarmuż, Maciej Sałaga, et al.
Neuro Endocrinology Letters|August 27, 2002
Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid systemPaolo Lissoni, Fabio Malugani, Ola Malysheva, et al.
Hormones and Behavior|May 9, 2013
A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' diseasePingping He, Xinping Ouyang, Shouhong Zhou, et al.
Journal of Alzheimer'S Disease : JAD|May 28, 2017
CD44 Splice Variants as Potential Players in Alzheimer's Disease PathologyElhanan Pinner, Yaron Gruper, Micha Ben Zimra, et al.
BMC Medicine|August 18, 2010
Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safetyAlan G Wade, Ian Ford, Gordon Crawford, et al.
Current Medical Research and Opinion|November 25, 2010
Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term responseAlan G Wade, Gordon Crawford, Ian Ford, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 14, 2017
Melatonin Receptor Agonist Piromelatine Ameliorates Impaired Glucose Metabolism in Chronically Stressed Rats Fed a High-Fat DietJun Zhou, Deng Wang, XiaoHong Luo, et al.
European Journal of Pharmacology|February 4, 2014
Piromelatine, a novel melatonin receptor agonist, stabilizes metabolic profiles and ameliorates insulin resistance in chronic sleep restricted ratsMeihua She, Xiaobo Hu, Zehong Su, et al.
European Journal of Pharmacology|July 9, 2017
Neu-P11, a novel MT1/MT2 agonist, reverses diabetes by suppressing the hypothalamic-pituitary-adrenal axis in ratsJun Zhou, Jin Zhang, XiaoHong Luo, et al.
Acta Biochimica Et Biophysica Sinica|March 31, 2016
Role of Neu-p11/luzindole in the regulation of insulin signaling pathways and insulin resistanceXiuping Li, Shichang Cai, Weidong Yin, et al.
Pageof 4